Myeloproliferative disorders can strike at any age, and they have no known cause. Symptoms, prognosis and progression can vary. Some patients may have slowly progressing disease that may not require any treatment beyond careful monitoring while others may progress to more advanced stages, including in some cases, AML, acute myelogenous leukemia. In this episode of Patient Power, sponsored by The University of Texas M. D. Anderson Cancer Center, Dr. Srdan Verstovsek explains the different myeloproliferative disorders, how they are treated and the advances being made through research and clinical trials, specifically JAK2. Also joining the program is his patient, Marty, who sought treatment at M. D. Anderson and is doing very well today.
In 2006, Marty was diagnosed with myelofibrosis during an annual physical and was told he had three to five years to live. Marty is the epitome of a powerful patient – when diagnoses, he turned to the internet to research his condition. He read about Dr. Verstovsek and the clinical trials he was conducting. Marty eventually met him at a conference, became Dr. Verstovsek’s patients, and enrolled in the JAK2 clinical trial.
Dr. Verstovsek explains the JAK2 trial and Marty’s participation. Dr. Verstovsek addresses how to determine the best treatment approach, considering that many myeloproliferative disorders have a “watch and wait” period. He stresses the importance of advances in research, how they are providing hope for the future. Dr. Verstovsek encourages listeners to participate in clinical trials. Listen now to learn more about myeloproliferative disorders.
Be the first to know about new programs and information with email alerts.